A randomized, placebo-controlled, multicenter, blinded phase I/II study of the safety of escalating doses of ocrelizumab (PRO70769) in subjects with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate.

Trial Profile

A randomized, placebo-controlled, multicenter, blinded phase I/II study of the safety of escalating doses of ocrelizumab (PRO70769) in subjects with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms ACTION
  • Sponsors Genentech
  • Most Recent Events

    • 24 Aug 2008 Status changed from active, no longer recruiting to completed.
    • 11 Nov 2007 Results reported at the 71st Annual Scientific Meeting of the American College of Rheumatology and the 42nd Annual Meeting of the Association of Rheumatology Health Professionals.
    • 16 Jun 2007 Results were reported at EULAR 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top